menu
    • menu
    [{"orgOrder":0,"company":"Neurimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NI006","moa":"Transthyretin (TTR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Inclisiran Sodium","moa":"PCSK9 mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin (TTR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"NI006","moa":"Transthyretin (TTR)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Neurimmune","amount2":0.76000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.76000000000000001,"dosageForm":"Infusion","sponsorNew":"Neurimmune \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aphaia Pharma \/ ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc.","highestDevelopmentStatusID":"6","companyTruncated":"Aphaia Pharma \/ ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc."},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"XXB750","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Amazentis","sponsor":"Goethe University","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Urolithin A","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Amazentis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amazentis \/ Goethe University","highestDevelopmentStatusID":"6","companyTruncated":"Amazentis \/ Goethe University"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QCZ484

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Safety of QCZ484 in Healthy and Mild Hypertensive Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 01, 2025

                            Lead Product(s) : QCZ484

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aphaia Pharma

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Aphaia Pharma

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmacodynamics and Pharmacokinetics of 3 New Developed Coated Glucose Beads in 20 Obese Healthy Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            February 06, 2023

                            Lead Product(s) : Glucose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : ACC GmbH Analytical Clinical Concepts, Germany | Nova-Clin Medical Research Center S.R.L., Romania | Bioclinica | Galephar Pharmaceutical Research (PR), Inc.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neurimmune

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Neurimmune

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NI006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : $760.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AstraZeneca and Neurimmune Sign Exclusive Global Collaboration and Licence Agreement to Develop and Commercial...

                            Details : Under the agreement, Alexion will be granted an exclusive worldwide licence to develop, manufacture and commercialise NI006. NI006, an ATTR depleter, a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies ...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $30.0 million

                            July 01, 2022

                            Lead Product(s) : NI006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : $760.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XXB750

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 14, 2022

                            Lead Product(s) : XXB750

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neurimmune

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Neurimmune

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NI006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : $760.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AstraZeneca and Neurimmune Close Exclusive Global Collaboration and Licence Agreement to Develop and Commercia...

                            Details : NI006 adds a novel and complementary approach to AstraZeneca and Alexion’s pipeline of investigational therapies focused on amyloidosis and strengthens the Company’s broader commitment to addressing cardiomyopathies that can lead to heart failure (HF...

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $30.0 million

                            January 03, 2022

                            Lead Product(s) : NI006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : $760.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inclisiran Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants Wit...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            February 26, 2021

                            Lead Product(s) : Inclisiran Sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neurimmune

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Neurimmune

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NI006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 24, 2020

                            Lead Product(s) : NI006

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Amazentis

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Amazentis

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Urolithin A

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Eurofins CDMO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single and Multiple Dose Study of AMAZ-02 to Evaluate Safety and Pharmacokinetics in Elderly Subjects

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            January 14, 2016

                            Lead Product(s) : Urolithin A

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Eurofins CDMO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LFF269

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 28, 2014

                            Lead Product(s) : LFF269

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed

                            F. Hoffmann-La Roche

                            Switzerland arrow
                            Vitafoods
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RO6836191

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in ...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            November 26, 2013

                            Lead Product(s) : RO6836191

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth